कंपनी का अवलोकन
Viemed Healthcare, Inc. operates within the healthcare sector, specifically focusing on the medical devices industry, where it delivers essential home medical equipment and post-acute respiratory healthcare services across the United States. The firm specializes in providing respiratory disease management solutions, which include comprehensive treatments for chronic obstructive pulmonary disease (COPD) and other respiratory conditions. This operational scope positions the company as a significant player in the home health and medical equipment market, serving patients who require ongoing support outside of traditional hospital settings. The company demonstrates substantial scale with a market capitalization of $378.31 million and an annual revenue of $270.28 million, supported by a workforce of 1382 employees. These financial figures indicate a mid-cap enterprise that has achieved a meaningful revenue base, suggesting a stable presence in a specialized niche rather than a massive conglomerate, yet one that commands significant market valuation relative to its book value.
वित्तीय स्वास्थ्य
Viemed Healthcare reports a trailing twelve-month revenue of $270.28 million, generating a net income of $14.93 million and an EBITDA of $50.45 million. The substantial gap between the $270.28 million in revenue and the $14.93 million in net income reveals a cost structure where operating expenses, including the cost of goods sold, administrative costs, and taxes, consume approximately 94.5% of gross sales before arriving at the bottom line. The company maintains a free cash flow of $15.72 million, which signifies a positive cash generation capability that provides the financial flexibility to fund operations, service debt, or invest in equipment without relying solely on external financing. Profitability is assessed through three distinct margins: a gross margin of 57.5%, which reflects high efficiency in manufacturing or sourcing respiratory equipment; an operating margin of 11.5%, indicating that general and administrative expenses are kept relatively low compared to sales; and a profit margin of 5.5%, which represents the final earnings available to shareholders after all obligations. Regarding liquidity and leverage, the company holds $13.50 million in cash against $15.95 million in debt, resulting in a debt-to-equity ratio of 11.11, which indicates a leveraged balance sheet where debt exceeds equity, yet the total debt remains manageable relative to cash reserves. Short-term liquidity is assessed via a current ratio of 1.18, suggesting the company has just enough current assets to cover its current liabilities, implying a need for careful working capital management. Finally, the return on equity stands at 11.1% while the return on assets is 7.3%, metrics that reveal management's effectiveness in utilizing shareholder capital and total assets to generate profits, with ROE exceeding ROA due to the leverage applied.
मूल्यांकन आकलन
The valuation of Viemed Healthcare is characterized by a trailing P/E ratio of 26.49 and a forward P/E of 24.50. The difference between the trailing and forward P/E ratios implies that the market expects earnings to grow in the future, as investors are willing to accept a lower multiple for anticipated future earnings compared to current historical performance. The price-to-book ratio is 2.63, indicating that the market values the company at a significant premium over its book value, suggesting confidence in the quality of its assets and future earnings potential. Alternative valuation metrics include a price-to-sales ratio of 1.40 and an EV/EBITDA of 7.59, which suggest the company is priced moderately relative to its revenue and enterprise value, offering a different perspective than earnings-based multiples. Price momentum is observed within a 52-week range bounded by a high of $10.06 and a low of $5.93; without the specific current share price, the precise position within this range cannot be calculated, but the range itself defines the volatility floor and ceiling for the stock. The beta value is 1.16, which means the stock exhibits higher price volatility relative to the broader market, moving more than 10% more than the market average in either direction during periods of fluctuation.
Growth & Income
The company demonstrates robust expansion with a revenue growth rate of 25.5% year-over-year and an earnings growth rate of 29.8% year-over-year. Earnings are growing at a faster pace than revenue, which implies that the company is likely benefiting from operational leverage, margin expansion, or efficiency improvements that allow profits to rise disproportionately to sales growth. As a non-dividend payer, Viemed Healthcare does not distribute cash to shareholders, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning the company retains all earnings to reinvest into growth initiatives such as expanding its respiratory care network or upgrading medical equipment fleets. This reinvestment strategy prioritizes capital appreciation over current income, catering to investors seeking growth in the medical device sector rather than dividend yield. Overall, the growth and income profile is defined by high single-digit to double-digit expansion in both revenue and profitability, coupled with a zero-dividend policy that directs cash flow toward business scaling rather than shareholder payouts.